Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899212 | 0.90 | KDM1A (0.47) | KMT2ACYP1A2CYP2C9CYP2C19ADORA1 | |
| SCHEMBL4907249 | 0.86 | KMT2A (0.41) | KMT2ACYP1A2CYP2C9CYP2C19ADORA1 | |
| SCHEMBL4907303 | 0.84 | CTSS (0.47) | KMT2ACYP1A2CYP2C9CYP2C19ADORA1 | |
| SCHEMBL4898198 | 0.82 | HPGD (0.41) | KMT2ACYP1A2CYP2C9CYP2C19ADORA1 | |
| SCHEMBL4906255 | 0.81 | ADORA1 (0.47) | KMT2AADORA1ADORA2BADORA2AALDH1A1 | |
| SCHEMBL4898439 | 0.81 | KDM1A (0.52) | KMT2ACYP1A2CYP2C9CYP2C19ADORA1 | |
| SCHEMBL4909018 | 0.80 | ADORA1 (0.56) | ADORA1ADORA2BADORA2AACHE | |
| SCHEMBL4911779 | 0.79 | CTSK (0.40) | KMT2AADORA1ADORA2AMEN1ACHE | |
| SCHEMBL4899380 | 0.79 | ADORA1 (0.53) | CYP1A2CYP2C19ADORA1ADORA2BADORA2A | |
| SCHEMBL4908292 | 0.79 | KMT2A (0.56) | KMT2AADORA1ADORA2BADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | KMT2A 3422/4885CYP1A2 1768/4885CYP2C9 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.